Personalis, Inc. (PSNL) · Peers
Personalis against the 24 other companies here in its SEC industry, Services-Medical Laboratories. Each figure is the one on the company's own page; the median is the peers', and the rank is among all 25, highest first.
Measure by measure
| Measure | PSNL | Peer median | Rank |
|---|---|---|---|
| Market value | $1.67B | median $1.01B | 12 of 25 |
| P/S | 24.0× | median 2.5× | 5 of 25 |
| FCF yield | -6.0% | median -1.5% | 18 of 25 |
| Gross margin | 12.7% | median 34.3% | 15 of 17 |
| Operating margin | -164.1% | median -9.6% | 21 of 23 |
| Net margin | -153.8% | median -5.6% | 21 of 23 |
| ROIC | -351.3% | median -12.2% | 22 of 23 |
| ROE | -45.6% | median -7.7% | 18 of 22 |
| Revenue growth (4y, yearly) | -5.0% | median 8.4% | 18 of 20 |
| Current ratio | 5.7× | median 4.8× | 11 of 25 |
| Stock pay / revenue | 15.7% | median 4.8% | 5 of 24 |
Green where Personalis is on the better side of the median, red where on the worse; no colour where higher is neither, like size or dividend yield.
The peers, largest first
| Company | Market value | P/E | ROIC | Score |
|---|---|---|---|---|
| PSNLPersonalis, Inc. | $1.67B | P/E – | -351.3% | 3.4 |
| NTRANatera, Inc. | $56.71B | P/E – | -31.4% | 4.0 |
| DGXQuest Diagnostics Incorporated | $25.94B | P/E 24.4× | 10.2% | 5.1 |
| LHLaboratory Corporation of America Holdings | $25.79B | P/E 25.7× | 8.2% | 4.8 |
| GHGuardant Health, Inc. | $21.28B | P/E – | -163.9% | 3.7 |
| CAICaris Life Sciences, Inc. | $8.64B | P/E 82.1× | 192.1% | 4.9 |
| RDNTRadNet, Inc. | $5.41B | P/E – | 3.2% | 3.6 |
| GRALGRAIL, Inc. | $5.26B | P/E – | -17.8% | 3.7 |
| BLLNBillionToOne, Inc. | $4.18B | P/E 111.0× | 42.9% | 5.1 |
| VCYTVeracyte, Inc. | $3.47B | P/E 30.3× | 8.0% | 6.5 |
| CDNACareDx, Inc. | $3.31B | P/E 29.8× | 164.4% | 6.1 |
| FTREFortrea Holdings Inc. | $2.14B | P/E – | -0.6% | 4.6 |
| LMRILumexa Imaging Holdings, Inc. | $1.04B | P/E 232.1× | – | 4.2 |
| CSTLCastle Biosciences Inc | $976.36M | P/E – | -11.4% | 4.8 |
| FLGTFulgent Genetics, Inc. | $545.08M | P/E – | -13.0% | 4.2 |
| YDESYD Bio Ltd | $419.07M | P/E – | – | 2.6 |
| BDSXBiodesix Inc | $249.64M | P/E – | -55.9% | 3.8 |
| XGNExagen Inc. | $187.02M | P/E – | -76.2% | 4.3 |
| BNRBurning Rock Biotech Ltd | $142.59M | P/E – | -74.0% | 5.2 |
| SERASera Prognostics, Inc. | $103.98M | P/E – | -227.8% | 3.2 |
| CFORCapForce Inc. | $43.39M | P/E – | 68.9% | 6.6 |
| MDXHMDxHealth SA | $10.61M | P/E – | -25.0% | 4.7 |
| AMSAmerican Shared Hospital Services | $8.51M | P/E – | -5.8% | 3.9 |
| ACONAclarion, Inc. | $5.33M | P/E – | -1069.5% | 3.4 |
| BGLCBioNexus Gene Lab Corp | $3.52M | P/E – | -30.6% | 4.1 |
The industry is the Standard Industrial Classification code the company registered with the SEC. It is a broad label: a peer group is a starting point for comparing, not proof that two businesses are alike. None of this is advice.